Compare Twist Bioscience Corp (TWST) vs Zillow Group Inc Class C (Z) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Twist Bioscience Corp vs Zillow Group Inc Class C — how do they compare? Twist Bioscience Corp trades at $125.52 (market cap $8.42B), while Zillow Group Inc Class C trades at $32.46 (market cap $7.31B). The key difference: Twist Bioscience Corp is the larger of the two by market cap, and Twist Bioscience Corp is trading nearer its 52-week high, Zillow Group Inc Class C nearer its low. Which is the better fit depends on your goals.
| TWST | Z | |
|---|---|---|
Market Cap | $8.42B | $7.31B |
Sector | Health | Media |
52-Week High | $153.10 | $90.35 |
52-Week Low | $24.16 | $29.41 |
Enterprise Value | $8.35B | $7.19B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Twist Bioscience (TWST) trades at $128.06, up 2.68% today, but remains below the analyst consensus price target of $106.14. The stock shows mixed technical signals with bearish overall momentum but bullish moving averages. Fundamentally, the company continues to report losses with a net income margin of -31.66% despite 23% revenue growth in Q3 2026. Recent news highlights AI-driven optimism and institutional buying interest.
TWST presents a high-risk growth story with strong analyst support (79% buy ratings) but persistent profitability challenges. The stock's valuation appears stretched with P/S of 18.09 and P/B of 18.89. Key catalysts include AI drug discovery partnerships and path to EBITDA breakeven, while risks include cash burn and competitive pressures in biotech.
Zillow Group (Z) trades at $32.36, down 6.45% amid a challenging housing market. The stock shows bearish technical signals with support at $30 and resistance at $34. Fundamentally, revenue growth continues (2025: $2.58B, 2026: $2.8B projected) with improving profitability (net margin turning positive at 1.96% in 2025). Recent Q2 2026 earnings beat expectations with $0.52 EPS versus $0.4459 expected, though the company faces regulatory scrutiny from a recent FTC settlement.
Despite near-term headwinds, Zillow's transition to an integrated transaction platform and strong rental market presence offer long-term growth potential. Key risks include housing market volatility, competitive pressures, and ongoing legal challenges. Analyst consensus price target of $52 suggests significant upside potential from current levels, though technical indicators remain bearish in the short term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →About Zillow Group Inc Class C
Zillow Group is an online real estate company that simplifies buying, selling, renting, and financing properties. It partners with agents, brokers, and landlords, combining technology with quality service. Its brands include Zillow, Trulia, StreetEasy, and Hotpads.
Read more on Z →
